Myocrisin (Sodium aurothiomalate) injection - Discontinuation

Sanofi can confirm that Myocrisin has been permanently discontinued. The discontinuation is due to a long-term shortage of the Active Pharmaceutical Ingredient (API) which means it is currently not possible to manufacture the product. The discontinuation is not due to any safety issues.

Myocrisin Solution for Injection currently on the market can continue to be used but patients should be switched to alternative treatments, under medical supervision. Sanofi are unable to recommend any alternative treatment options as this is a clinical decision that would need to be made by the treating healthcare professional.

Based on current forecasts, supply of Myocrisin Solution for Injection 100mg/ml is expected to last until the end of June 2019 and Myocrisin Solution for Injection 20mg/ml is expected to last until the end of July 2019.

If you require any further information regarding the availability of Myocrisin, please contact our Sanofi Customer Services team on 0800 854 430 or GB-customerservices@sanofi.com.

The Summary of Product Characteristics (SmPC) for Myocrisin is available at https://www.medicines.org.uk/emc/.

This information is supplied as a professional courtesy in response to your enquiry. It is intended to provide pertinent data that may assist you in forming your own conclusions and making your own decisions. This information is not intended to advocate any indication, dosage, or other claim that is not covered in the Summary of Product Characteristics (SmPC). Please note that Sanofi’s response, and any attached literature is for your own personal use, and due to copyright may not be forwarded/published.

I hope that this information is useful to you. Should you have any further enquiries, please contact us by email at uk-medicalinformation@sanofi.com or by telephone on 0845 372 7101.